A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples